Losmapimod Demonstrates Significant Slowing of FSHD
Durability of treatment response on reachable workspace was observed among those who continued losmapimod throughout the 96-week period and those who switched from placebo. New long-term findings from the phase 2b ReDUX4 trial (NCT04003974) showed that treatment with losmapimod (Fulcrum…